bims-cagime Biomed News
on Cancer, aging and metabolism
Issue of 2026–04–05
29 papers selected by
Kıvanç Görgülü, Technical University of Munich



  1. Mol Cell. 2026 Apr 02. pii: S1097-2765(26)00163-2. [Epub ahead of print]86(7): 1260-1274.e4
      Ferroptosis is an iron-dependent form of cell death converging on lipid peroxidation first identified by examining compounds with enhanced lethality to KRAS mutant cells. Despite over 90% of pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations, PDAC exhibits relative resistance to ferroptosis compared with other tumor types, and the mechanisms behind this resistance remain unclear. Here, we report that exposure to pancreatic tumor interstitial fluid in synergy with hypoxia induced robust protection against ferroptosis in a manner dependent on the hypoxia-inducible transcription factor 2 (HIF-2). HIF-2 upregulates the expression of both components of the system Xc- cystine transporter and transsulfuration pathway enzymes CBS and CTH to increase intracellular cysteine levels, enabling anti-ferroptotic glutathione production. HIF-2 also induces the Parkin mitophagy factor and suppresses mitochondrial function and reactive oxygen species (ROS) generation. Altogether, our findings uncover an unforeseen role of the HIF-2 transcription factor as a coordinator of anti-ferroptotic mechanisms in pancreatic cancer.
    Keywords:  HIF-2 transcription factor; ferroptosis; hypoxia; pancreatic ductal adenocarcinoma
    DOI:  https://doi.org/10.1016/j.molcel.2026.03.007
  2. Nat Metab. 2026 Apr 01.
      Acinar-to-ductal metaplasia (ADM) is a reversible cell state that facilitates pancreas repair following injury. Oncogenic KRAS mutations can progress ADM to pancreatic intraepithelial neoplasia (PanIN) and pancreatic ductal adenocarcinoma (PDAC). However, the metabolic alterations in these precancerous lesions are understudied. Here, we identify global changes in central carbon metabolism genes and metabolites during ADM formation. In particular, NRF2-target genes are significantly induced in ADM. Among these, we focus on genes encoding NADPH-producing enzymes glucose-6-phosphate dehydrogenase (G6PD) and malic enzyme 1 (ME1), which participate in the regulation of oxidative stress. In mouse models of pancreatic tumourigenesis, G6PD deficiency or Me1 loss increases reactive oxygen species and lipid peroxidation, which is accompanied by accelerated formation of ADM and PanIN lesions. Notably, Me1 loss, but not G6PD deficiency, promotes faster PDAC progression. We demonstrate that oxidative stress is required for ADM, as pharmacological antioxidant treatment attenuates ADM progression in vivo and ex vivo. Conversely, depleting the antioxidant glutathione promotes precancerous lesions in primary human acinar cells and in mice. Together, our findings shed light on metabolic reprogramming in the precancerous pancreas.
    DOI:  https://doi.org/10.1038/s42255-026-01496-x
  3. Nat Metab. 2026 Apr 01.
      Acinar-to-ductal metaplasia (ADM) contributes to pancreatic repair after injury1. However, persistent ADM, combined with KRAS mutation, leads to the development of precancerous pancreatic intraepithelial neoplasia (PanIN) that can progress into pancreatic ductal adenocarcinoma (PDAC)2. While PDAC development is well documented, the metabolic rewiring that occurs during early events such as ADM is poorly understood. Here we show that aldehyde dehydrogenase 1 family member L2 (ALDH1L2), an NADPH-producing mitochondrial enzyme of the one-carbon pathway, limits reactive oxygen species (ROS) and formate production in pancreatic acinar cells. However, ALDH1L2 expression decreases progressively during ADM and is completely absent in pancreatic ductal cells. ALDH1L2 loss elevates ROS and promotes ADM in a model of pancreatitis and accelerates tumour progression in models of pancreatic cancer. We also show that formate increases during PDAC progression in mice and humans. Overall, our findings identify ROS as a driver of ADM and suggest that circulating formate may serve as a biomarker for PDAC progression.
    DOI:  https://doi.org/10.1038/s42255-026-01456-5
  4. Cell. 2026 Mar 30. pii: S0092-8674(26)00269-2. [Epub ahead of print]
      Chimeric antigen receptor (CAR) T cells have transformed hematologic cancer therapy but remain limited in solid tumors by antigen heterogeneity and a suppressive, pro-fibrotic microenvironment. We previously identified the urokinase plasminogen activator receptor (uPAR) as upregulated in senescent, pro-fibrotic cells and showed that uPAR-directed CAR T cells could safely reverse fibrosis in mice. Integrative analyses now reveal that uPAR is broadly expressed in solid tumors enriched for TP53 and RAS pathway mutations. These tumors adopt a progenitor-like state supported by a niche of uPAR-positive stromal cells with senescence features. Human uPAR CAR T cells eliminate tumor cells and their stromal support, induce durable regressions across diverse models, eradicate systemic metastases, and are potentiated by senescence-inducing therapies. Importantly, these cells achieve robust antitumor activity without sustained myelosuppression in mice reconstituted with human immune systems. Together, these findings establish uPAR as a broadly applicable CAR T target capable of overcoming major barriers in solid tumor therapy.
    Keywords:  CAR T cells; fibrosis; p53; senescence; senolytic; tumor microenvironment; uPAR
    DOI:  https://doi.org/10.1016/j.cell.2026.03.002
  5. Trends Endocrinol Metab. 2026 Apr 02. pii: S1043-2760(26)00065-2. [Epub ahead of print]
      Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, driven by aggressive biology, profound therapy resistance, and scarce treatment options. Beyond classical metabolic rewiring, recent discoveries reveal that lipid metabolism plays a central and previously underappreciated role in PDAC progression. Emerging evidence shows that fatty acids, cholesterol, lysophospholipids, sphingolipids, and oxidized lipid species actively shape oncogenic signaling, influence stromal and immune interactions, and contribute to metastasis and treatment evasion. In this review, we highlight these recent advances and discuss how lipid-driven circuits intersect with major oncogenic pathways, including KRAS effectors and phosphoinositide 3-kinase-AKT. By integrating mechanistic insights with therapeutic perspectives, we outline new opportunities to exploit lipid-based vulnerabilities in pancreatic cancer.
    Keywords:  lipid metabolic rewiring; lipid signaling; oncogenic pathways; pancreatic ductal adenocarcinoma; therapy resistance; tumor–stroma interactions
    DOI:  https://doi.org/10.1016/j.tem.2026.03.004
  6. Nat Methods. 2026 Mar 30.
      Lipids play a central role in a multitude of biological functions associated with cancer, obesity, diabetes, cardiovascular and neurological pathologies. However, sensing and mapping of lipid classes in living cells remains challenging. Here we introduce a label-free approach to lipid imaging, which differentiates lipid species in living cells by hyperspectral mid-infrared detection of single-bond vibrational modes within the fingerprint region. Hyperspectral fingerprint optoacoustic microscopy is shown to resolve phosphatidylcholine, sphingomyelin or cholesterol in test samples and in synthetic giant unilamellar vesicles used as models of cell membranes. Then, mapping of total cholesterol and sphingomyelin content and accumulation dynamics are demonstrated in living cells. Hyperspectral fingerprint optoacoustic microscopy demonstrates sensitivity not only in discerning lipids with substantially different chemical structures, such as cholesterol and phospholipids, but also lipids that are chemically similar, such as sphingomyelins and glycerophospholipids.
    DOI:  https://doi.org/10.1038/s41592-026-03025-w
  7. Trends Cell Biol. 2026 Mar 30. pii: S0962-8924(26)00038-3. [Epub ahead of print]
      Ferroptosis is an iron-dependent programmed cell death that involves lipid peroxidation. Ferroptosis represents a critical process underlying tumorigenesis and multiple pathological disorders. Recently, lysosomes have been found to orchestrate ferroptotic signaling, linking iron metabolism, oxidative homeostasis, and selective autophagy. Furthermore, lysosomal membrane disruption leads to the release of intraluminal iron and cathepsins, thereby facilitating ferroptotic damage, whereas lysosomal exocytosis acts in the opposite direction to limit ferroptosis. Therefore, pharmacological modulation of lysosomal activities could be used to treat drug-resistant tumors or protect normal tissues against ferroptosis-related injuries. In this review, we summarize how lysosomes control ferroptosis, focusing on the regulation through lysosomal contents, pH, degradation processes, and exocytosis. We also discuss possible therapeutics that target lysosomes to modulate ferroptosis-associated diseases.
    Keywords:  LMP; autophagy; ferritinophagy; ferroptosis; iron; lysosome
    DOI:  https://doi.org/10.1016/j.tcb.2026.03.007
  8. Cell. 2026 Mar 31. pii: S0092-8674(26)00279-5. [Epub ahead of print]
      Delineating how acquired nutrients are partitioned into different intracellular pathways and how these various fates support distinct functions in T cells is limited. We show that CD8+ T cells acquire cysteine to serve both as a substrate for glutathione (GSH) production, which modulates effector functions, and to cede its sulfur for NFS1-dependent FeS cluster synthesis, which supports proliferation. NFS1 deletion in activated CD8+ T cells promotes exhaustion and dampens anti-cancer immunity, whereas blocking cysteine flux into GSH or enforcing FeS metabolism enhances tumor control. This role for disrupted FeS metabolism in T cell exhaustion is echoed in data from human hepatocellular carcinoma. Elucidating how different intracellular pathways use cysteine enables targeted control of cysteine flux to retain the beneficial effects of cysteine while abolishing those that restrain function. We illustrate this concept for one metabolite, cysteine, but it is likely to apply to other metabolites relevant for immune cell function.
    Keywords:  CD8+ T cells; Fe-S clusters; T cell exhaustion; anti-tumor immunity; cysteine; glutathione; immunometabolism; iron uptake; lipid peroxidation; mitochondria
    DOI:  https://doi.org/10.1016/j.cell.2026.03.012
  9. Cancer Discov. 2026 Apr 01. 16(4): 656-659
      Metastasis is a multiorgan disease in which disseminated cancer cells undergo profound, tissue-specific reprogramming that reshapes their identity, vulnerabilities, and therapeutic responses. We argue for an organ-informed precision oncology framework that integrates these site-imposed programs into treatment design.
    DOI:  https://doi.org/10.1158/2159-8290.CD-25-2052
  10. Sci Adv. 2026 Apr 03. 12(14): eaea6734
      Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with a dense desmoplastic stroma and an immunosuppressive tumor microenvironment that contribute to therapeutic resistance. Here, we identify plasminogen activator inhibitor 1 (PAI1) as a stroma-derived mediator of immune evasion and tumor progression in PDAC. PAI1 is predominantly produced and secreted by cancer-associated fibroblasts, and its genetic ablation in the stromal compartment impairs tumor growth. Mechanistically, hypoxia induces PAI1 expression in fibroblasts, which in turn shifts macrophages toward immunosuppressive phenotypes and suppresses CD8+ T cell infiltration and function. We further show that tissue plasminogen activator (tPA), a direct PAI1 target, is also secreted by fibroblasts and supports antitumor CD8+ T cell responses. Notably, elimination of stromal tPA promotes immunosuppressive macrophage phenotypes, reduces CD8+ T cell infiltration, and accelerates PDAC progression. These findings define a previously unrecognized PAI1-tPA regulatory axis within the tumor stroma that modulates antitumor immunity. Targeting this pathway may provide a therapeutic opportunity to overcome stroma-driven immune suppression in PDAC.
    DOI:  https://doi.org/10.1126/sciadv.aea6734
  11. Cancer Discov. 2026 Apr 01. 16(4): 637-643
      We propose a physics-based framework in which cancer cell state is defined by position and velocity in a continuous space of directly measurable physical variables-cell surface area (S) and volume (V)-and motion through S-V space as an interpretable proxy for plasticity. Therapy generates S-V vector fields that govern trajectories, enabling the design of drug combinations to steer heterogeneous cell populations toward nonviable states, offering a predictive and physically interpretable alternative to therapies directed against oncogenic mutations and/or predefined cell subpopulations.
    DOI:  https://doi.org/10.1158/2159-8290.CD-26-0083
  12. Nat Med. 2026 Mar 30.
      Quemliclustat potently inhibits CD73, a key enzyme producing immunosuppressive adenosine. In a phase 1b trial (ARC-8), we evaluated safety and efficacy of quemliclustat combined with gemcitabine/nab-paclitaxel (G/nP) with or without zimberelimab (anti-programmed cell death protein 1 (PD-1)) in first-line metastatic pancreatic ductal adenocarcinoma (PDAC). During the dose-escalation phase, 22 patients were enrolled across five dose levels of quemliclustat (25 mg, 50 mg, 75 mg, 100 mg or 125 mg) with G/nP + zimberelimab. During the dose-expansion phase, 116 patients were enrolled, beginning with a single-arm, non-randomized cohort receiving quemliclustat 100 mg + G/nP + zimberelimab, followed by a randomized cohort in which patients were assigned in a 2:1 ratio to receive quemliclustat 100 mg + G/nP with or without zimberelimab. The primary endpoint was safety and tolerability; secondary endpoints included assessments of clinical activity and survival. In all treatment arms, the safety profile was consistent with that of G/nP. Clinical response rates and survival outcomes were encouraging. NR4A family gene expression was upregulated by adenosine in vitro and by chemotherapy in human PDACs. High tumor NR4A expression was associated with improved overall survival (OS) in ARC-8 but not in two external cohorts from the PRINCE (G/nP + nivolumab (nivo)) or Morpheus-PDAC (G/nP) trials. Spatial tissue analyses revealed a scarcity of activated T cells near regions with high NR4A1 expression, consistent with an immunosuppressed tumor microenvironment. In paired pretreatment/posttreatment biopsies, maximal downregulation of NR4A expression was associated with T cell activation and improved OS, pointing to a biological link between tumor adenosine and clinical benefit. ClinicalTrials.gov identifier: NCT04104672 .
    DOI:  https://doi.org/10.1038/s41591-026-04283-z
  13. Cell Rep. 2026 Mar 30. pii: S2211-1247(26)00266-4. [Epub ahead of print]45(4): 117188
      Pancreatic ductal adenocarcinoma (PDAC) is characterized by dense stromal fibrosis that promotes immune exclusion and treatment resistance, yet the upstream drivers of this pro-fibrotic cascade remain poorly defined. Here, we identify phosphoinositide 3-kinase δ (PI3Kδ) as a previously unrecognized driver of fibrosis in PDAC. Pharmacological inhibition of PI3Kδ reduces collagen deposition while enhancing the infiltration of activated CD8+ T cells, thereby reprogramming the tumor microenvironment toward an antitumor state. Mechanistically, we reveal that PI3Kδ regulates the biosynthesis of lysophosphatidic acid (LPA), a key lipid mediator of stromal remodeling, by controlling phosphatidylcholine-derived precursors in both cancer cells and stromal fibroblasts. By regulating both LPA-driven stromal remodeling and immune suppression, PI3Kδ emerges as a central regulator of the PDAC tumor microenvironment. Co-inhibition of autotaxin, an enzyme contributing to LPA production, and PI3Kδ further amplifies stromal disruption and improves chemo-immunotherapy efficacy in preclinical PDAC models. These findings position PI3Kδ as a central therapeutic target in PDAC, offering a dual-action strategy to simultaneously dismantle stromal fibrosis and immune suppression.
    Keywords:  CP: cancer; CP: immunology; immunosuppression; pancreatic ductal adenocarcinoma; targeted therapies; tumor lipid metabolic regulation; tumor microenvironment
    DOI:  https://doi.org/10.1016/j.celrep.2026.117188
  14. Nat Commun. 2026 Mar 31. pii: 3155. [Epub ahead of print]17(1):
      Biomolecular condensates, essential for cellular organization, possess mesoscale properties largely governed by hydrophobicity, influencing molecule partitioning and material characteristics like viscosity, surface tension, and hydration. While hydrophobicity's role is increasingly recognized, its impact on membrane-condensate interactions remains unexplored. Here, we combine hyperspectral imaging of an environment-sensitive dye and phasor analysis, to quantitatively map the local dielectric permittivity of both condensates and their environment with pixel resolution. This robust method senses the immediate molecular vicinity of the dye and reveals a surprisingly broad range of condensate permittivities, spanning from oil-like to water-like values. Importantly, we uncover that membrane affinity is not dictated by condensate permittivity itself, but by the permittivity contrast with their surroundings. Indeed, membrane wetting affinity is found to scale linearly with this permittivity contrast, unveiling a unifying dielectric principle governing condensate-membrane interactions. Compatible with live-cell and in vitro imaging, this technique provides quantitative insights into condensate biophysics and function and opens new avenues for studying biomolecular condensate biology.
    DOI:  https://doi.org/10.1038/s41467-026-71273-7
  15. RSC Chem Biol. 2026 Mar 25.
      Lipid droplets (LDs) are ubiquitous intracellular organelles that store neutral lipids such as triacylglycerols and sterol esters within a phospholipid monolayer decorated by a specialized proteome. Far from being inert depots, LDs are highly dynamic hubs that integrate lipid storage with cellular and systemic metabolic regulation. Their biogenesis, growth, remodeling, and catabolism are tightly controlled by nutrient status, hormonal signaling, and cellular stress, and are coupled to key metabolic pathways including β-oxidation, lipogenesis, membrane synthesis, and signaling lipid production. Aberrant LD dynamics coexist with a broad spectrum of metabolic pathologies, from obesity and insulin resistance to metabolic dysfunction-associated steatotic liver disease, lipodystrophies, and cancer. In this review, we discuss current concepts of LD biogenesis and expansion, cytosolic lipolysis and lipophagy, and the physical and functional interactions of LDs with mitochondria, peroxisomes, endoplasmic reticulum, and lysosomes. We highlight how tissue-specific LD biology in adipose tissue, liver, skeletal muscle, pancreatic β-cells, and immune cells shapes systemic energy homeostasis and the response to metabolic stress. Particular emphasis is placed on chemical biology and imaging approaches that have transformed our ability to visualize and manipulate LDs in space and time, including fluorescent lipid probes, metabolic labeling, organelle-targeted proximity labeling, lipidomics, and functional screening. Finally, we outline the opportunities and challenges in therapeutically targeting LD dynamics for metabolic disorders. This includes the emerging concept of exploiting LDs as drug and nucleic acid delivery platforms. We also discuss the outstanding questions that need to be addressed in order to safely use LD biology for clinical benefit.
    DOI:  https://doi.org/10.1039/d6cb00081a
  16. Nat Cell Biol. 2026 Apr 01.
      Trogocytosis, the transfer of plasma membrane fragments during cell-cell contact, offers potential for macromolecular delivery but is limited by the uncertain fate of trogocytosed molecules, restriction to membrane cargo and unclear generalizability. Here we demonstrate that donor cells engineered with designed receptors specific to surface ligands can transfer proteins to recipient cells through direct contact. We identified key engineering principles for enhancing transfer and ensuring cargo functionalization, including receptor design, pH-responsive membrane fusion, inducible cargo localization and release, and subcellular translocation. The method is broadly applicable across diverse cell types and operates through a dynamin- and endosome acidification-dependent pathway. Exploiting these findings, we developed TRANSFER, a versatile delivery system with programmable cell type specificity and tunability. TRANSFER can sense multiple ligand inputs, deliver large therapeutic protein cargos and mediate genome editing. The study establishes trogocytosis as a programmable, versatile framework for cell-based macromolecular delivery.
    DOI:  https://doi.org/10.1038/s41556-026-01920-0
  17. Methods Cell Biol. 2026 ;pii: S0091-679X(25)00197-9. [Epub ahead of print]204 285-299
      Lysosomes are involved in the transport, degradation, and recycling of macromolecules through the autophagy and endocytosis pathways. Cholesterol is taken up by cells through the internalization of low-density lipoprotein (LDL) via LDL receptor-mediated endocytosis or micropinocytosis. Free cholesterol generated by the action of acid lipases contained in lysosomes can be transferred to other organelles. Dysfunctions in either cholesterol uptake or release from lysosomes can compromise the function and integrity of these organelles, thereby contributing to the pathogenesis of lysosomal storage disorders. We previously showed that some cationic amphiphilic drugs (CADs) mimic the phenotype of lysosomal storage disorders by inducing lysosomal cholesterol accumulation followed by lysosomal damage. Here, we describe two fluorescence microscopic methods for the visualization of cholesterol accumulation in lysosomes in response to the CAD leelamine. In the first method, the cell-permeable cholesterol analog labeled with the fluorophore BODIPY is used. In the second method, endogenous cholesterol-rich microdomains are labeled with filipin complex. Both methods imply the additional visualization of the lysosomal associated membrane protein 2 (LAMP2) by immunofluorescence. Finally, the role of lysosomal cholesterol accumulation in the induction of lysosomal membrane permeabilization (LMP) was assessed through a method based on the recruitment of Galectin-3 on damaged lysosomes.
    Keywords:  BODIPY-cholesterol; Cancer; Filipin complex; Galectin-3; High-throughput fluorescence microscopy; LAMP2; Lysosomal membrane permeabilization
    DOI:  https://doi.org/10.1016/bs.mcb.2025.09.009
  18. Annu Rev Biochem. 2026 Mar 30.
      Integral membrane proteins play critical roles in mammalian cells, ranging from mediating cell-cell interactions to regulating apoptosis. These increasingly diverse functions necessitated the evolution of membrane proteins with more complex biophysical properties and architectures. In turn, specialized complexes called insertases have coevolved to integrate these proteins into the appropriate lipid bilayer. Notably, key sites of membrane protein biogenesis such as the endoplasmic reticulum and the outer and inner membranes of the mitochondria rely on distinct sets of insertases that work in concert, each specializing in membrane protein segments with particular features or properties. Here, we describe recent discoveries that shed light both on the molecular mechanisms of these insertases and on the many distinct pathways required for the insertion and folding of the mammalian membrane proteome.
    DOI:  https://doi.org/10.1146/annurev-biochem-080125-020218
  19. Methods Cell Biol. 2026 ;pii: S0091-679X(25)00194-3. [Epub ahead of print]204 171-192
      Lysosomotropism refers to the ability of certain basic lipophilic compounds to accumulate in lysosomes via pH partitioning. Various drugs including anticancer agents are trapped in lysosomes, and this process can prevent such drugs from reaching their primary target, thereby limiting their effectiveness. Strategies aimed at preventing drug sequestration or inducing drug release from lysosomes have garnered considerable interest. Chloroquine is a widely used anti-malarial drug that triggers lysosome membrane permeabilization (LMP) to liberate sequestered drugs from these organelles. In this study, we first evaluate the lysosomotropism of various fluorescent anticancer agents in silico. Next, we outline a simple, fast and robust method for the visualization and quantification of their lysosomal sequestration and release by fluorescence microscopy. The method is used on live cells and consists of two steps: (i) visualization of the compounds in lysosomes by analyzing their colocalization with a specific fluorescent lysosomal marker, and (ii) assessment of drug release from lysosomes. Furthermore, we present fluorescence microscopy protocols for monitoring LMP by analyzing the subcellular localization of LGALS3 (Galectin-3), which normally distributes diffusely in the cytoplasm but translocates into lysosomes upon LMP. This can be achieved on fixed cells by detecting endogenous LGALS3 with immunostaining or by the visualization of a transgenic LGALS3-mCherry fusion protein on live cells. Altogether, these methods facilitate qualitative and quantitative fluorescence imaging of lysosomal sequestration and liberation of lysosomotropic drugs.
    Keywords:  Cancer; Cell biology; Drug release; High-content imaging; LGALS3; Lysosomal membrane permeabilization; Lysosomotropic agents; Resistance to therapy; TFEB; Transcription
    DOI:  https://doi.org/10.1016/bs.mcb.2025.09.006
  20. Support Care Cancer. 2026 Apr 01. pii: 395. [Epub ahead of print]34(4):
       PURPOSE: Body-composition indices beyond body mass index (BMI) are increasingly being investigated as prognostic cancer markers. In pancreatic cancer, the prognostic relevance of skeletal muscle and adipose tissue compartments remains uncertain, with studies yielding inconsistent findings. We examined whether early on-treatment changes in subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT), and skeletal muscle index (SMI) are associated with unresectable pancreatic cancer prognosis.
    METHODS: This retrospective cohort study comprised patients with unresectable pancreatic cancer who received chemotherapy between 2019 and 2024. Baseline and 3-month computed tomography (CT) scans at L3 were analyzed to quantify SAT, VAT, and SMI, calculating percent changes (Δ%). A 3-month landmark approach was applied to survival analyses. Associations with overall survival (OS) were examined using Cox models; discrimination with receiver operating characteristic curves; and survival differences using Kaplan-Meier and log-rank tests.
    RESULTS: Sixty-nine patients were included (median age, 71 years; median OS, 12.0 months). Greater preservation of SAT Δ% was associated with reduced mortality risk (HR per tertile step, 0.64; 95% confidence interval, 0.44-0.94), whereas VAT and SMI changes were not significant. SAT Δ% achieved the highest AUC for classifying short- vs long-term survival (0.73) compared with VAT (0.65) and SMI (0.52). The Kaplan-Meier analysis showed significant separation between extreme SAT tertiles (p = 0.02).
    CONCLUSION: Early SAT loss was more strongly associated with poor prognosis than concurrent VAT or SMI changes. Serial assessment of SAT on routine CT may enhance early risk stratification in unresectable pancreatic cancer.
    Keywords:  Pancreatic neoplasms; Prognosis; Sarcopenia; Subcutaneous fat
    DOI:  https://doi.org/10.1007/s00520-026-10614-0
  21. Genome Biol. 2026 Mar 31.
      Understanding how genetic variation shapes tissue structure is crucial for disease biology, yet scalable, general-purpose frameworks for genetic analysis of histology traits are lacking. We present HistoGWAS, a framework for genome-wide association studies of histology data that leverages foundation models for automated trait definition, variance component models for efficient association testing, and generative models for variant effect interpretation. Applied to 11 tissues from the Genotype-Tissue Expression project, HistoGWAS identifies four genome-wide significant loci associated with tissue histology-tissue quantitative trait loci (tissueQTLs)-which we link to molecular changes and complex traits. Power analyses demonstrate scalability to population-scale histology cohorts.
    Keywords:  Colocalization; Generative models; Genome-wide association studies; Histology; Kernel methods; Semantic autoencoder; Variance component test
    DOI:  https://doi.org/10.1186/s13059-026-04031-z
  22. J Cachexia Sarcopenia Muscle. 2026 Apr;17(2): e70262
       BACKGROUND: The KPC mouse model of pancreatic cancer is gaining use in research, but detailed understanding of ingestive behaviour changes in this and other cachexia models is limited.
    METHODS: Male C57BL/6 J mice (7 weeks) were maintained under standard feed (PicoLab5L0D) and housing conditions (12:12 h; Light:Dark). Spontaneous feeding was observed in a Comprehensive Lab Animal Monitoring System: meal size, frequency, intermeal intervals and satiety ratio (i.e., time between meals divided by kcal energy in the preceding meal). Feeding was observed at baseline and over time after intraperitoneal injection syngeneic KPC pancreatic adenocarcinoma cells. Separate cohorts of mice were used to study homeostatic feeding responses at baseline and on Day 14 after KPC injection (KPC_14). These responses were fasting-evoked refeeding, ghrelin injection (1 mg/kg) and lights-out cue.
    RESULTS: Spontaneous food intake declined by 50% by 14 days after tumour injection. At baseline, food intake was observed during 23 of 24 h daily; at KPC_14, hours without any food intake increased from 1 to 12 (p ≤ 0.0001). At KPC_14, intermeal intervals increased (light cycle: 60.5 ± 11.2 vs. 146.4 ± 19.6 min; p < 0.0001; dark cycle: 26.0 ± 3.8 vs. 42.0 ± 5.5 min; p = 0.0045), and the satiety ratio tripled (light cycle: 23.1 ± 5.9 vs. 69.4 ± 10.5 min/0.1 kcal; p < 0.0001; dark cycle: 11.3 ± 3.4 vs. 27.1 ± 5.0 min/0.1 kcal; p = 0.0028). By contrast, meal size and ingestion rate were unchanged. At KPC_14 mice showed reduced responses to homeostatic feeding cues. After 12-h starvation, refeeding intake during 4 h was 0.81 ± 0.3 g vs. 0.39 ± 0.19 g at KPC_14 (-52%, p = 0.02). Ghrelin response was also blunted 0.66 ± 0.19 g vs. 0.42 ± 0.27 g at KPC_14 (-36%, p = 0.005). Mice responded to lights-out with ~ 4 h of vigorous feeding, ingesting a total of 0.94 ± 0.2 g at baseline; this amount was reduced to 0.55 ± 0.3 g (-41%, p < 0.01) at KPC_14, predominantly due to a steep decline in feeding after the end of the first dark hour.
    CONCLUSIONS: Mice with KPC show response to homeostatic feeding cues; however, these were of diminished amplitude and sustainability. Large increases in intermeal interval and satiety ratio were notable, with mice eating nothing at all for extended periods of time, consistent with enhanced satiety and/or a failure to generate signals sufficient to generate a new feeding event.
    Keywords:  appetite; cachexia; calorimetry, indirect; disease models, animal; energy metabolism; feeding behaviour; ghrelin; mice, inbred C57BL; pancreatic neoplasms
    DOI:  https://doi.org/10.1002/jcsm.70262
  23. Cell. 2026 Mar 27. pii: S0092-8674(26)00273-4. [Epub ahead of print]
      The laboratory mouse is a key model system for biomedical research, yet body-wide measurement tools are lacking. Here, we generate spatiotranscriptomics profiles of whole-mouse sections that accurately capture histological regions. We spatially assign 379 cell types across whole-mouse section profiles by building a reference dataset of 59M single cells coupled with a scalable computational method for cell-type assignment. Moreover, we exploit these whole-mouse profiles to create a machine learning pipeline, LABEL, which enables pan-body annotation of tissues and cell types on histology images from H&E-stained sections. Lastly, we apply whole-mouse spatial profiling to map systemic inflammation in endotoxemia, which delineates organism-wide changes in gene expression programs across tissues and cell types. Together, our work paves the way for body-wide studies of the molecular and cellular processes that govern the organismal biology of the laboratory mouse across space, time, and conditions.
    Keywords:  Array-seq; endotoxemia; inflammation; machine learning; spatial transcriptomics; whole-body
    DOI:  https://doi.org/10.1016/j.cell.2026.03.006
  24. Eur J Cancer. 2026 Mar 20. pii: S0959-8049(26)00463-6. [Epub ahead of print]239 116683
       BACKGROUND: This study aimed to determine the optimal second-line treatment strategy in patients with metastatic pancreatic cancer, hypothesizing that liposomal irinotecan (nal-IRI) combined with S-1 would be superior to nal-IRI with 5-fluorouracil (5-FU)/leucovorin (LV).
    METHODS: This was an international, multi-center, open-label, randomized phase I/II superiority trial. Patients with pancreatic adenocarcinoma, previously treated with gemcitabine-based treatment, were enrolled. Patients were randomly allocated to receive either nal-IRI plus S-1 (S-1 arm) or nal-IRI plus 5-FU/LV (5-FU arm). The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), (serious) adverse events (SAEs), response rate, and health-related quality of life. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using a Cox model. This trial is registered with ClinicalTrials.gov (NCT03986294) and is completed.
    RESULTS: Between November 10, 2021 and May 23, 2023, 120 patients were randomized to the S-1 arm (n = 61) or the 5-FU arm (n = 59). Three patients were excluded due to ineligibility. Median PFS was 2.2 months in the S-1 arm vs. 3.3 months in the 5-FU arm (HR 1.27; 95% CI 0.84-1.91, p = 0.26). Median OS was 6.0 months in the S-1 arm vs. 9.1 months in the 5-FU arm (HR 1.47; 95% CI 0.99-2.17, p = 0.054). The most common grade 3-4 AEs were diarrhea (13.8%) and nausea (10.3%) in the S-1 arm, and diarrhea (14.0%), asthenia and mucositis (both 7.0%) in the 5-FU arm.
    CONCLUSION: Second-line treatment with nal-IRI plus S-1 did not improve PFS and OS compared to nal-IRI plus 5-FU/LV in patients with metastatic pancreatic cancer following first-line gemcitabine-based chemotherapy.
    Keywords:  5-FU; Liposomal irinotecan; Metastatic pancreatic cancer; Overall survival; Pancreatic cancer; Progression-free survival; Quality of life; S-1; Second-line treatment
    DOI:  https://doi.org/10.1016/j.ejca.2026.116683
  25. J Physiol. 2026 Apr 01.
      Excitable tissues like the brain, peripheral nerves, skeletal muscles and the heart share a common dependence on voltage-gated sodium (Nav) channels for the initiation and propagation of action potentials (APs). These Nav channels exhibit unique biophysical properties tailored to their specific cellular environments. Here, we explore the interactions between Nav channel availability and resting membrane potential across a spectrum of cell types, including inhibitory GABAergic neurons, excitatory glutamatergic neurons, skeletal muscles, cardiomyocytes and dorsal root ganglion neurons. We highlight how these interactions, modulated by post-translational modifications and in relation to spatial localizations, are critical for maintaining physiological function and how even small shifts in channel properties can have significant pathophysiological consequences. In addition, we discuss the implications for drug discovery, emphasizing the need to consider the native cellular environment in developing Nav-targeting therapies. This perspective provides a framework for understanding the nuanced role of Nav channels in health and disease.
    Keywords:  availability; muscle; neuron; resting membrane potential; voltage‐gated sodium channel
    DOI:  https://doi.org/10.1113/JP290383
  26. J Cell Sci. 2026 Mar 15. pii: jcs263933. [Epub ahead of print]139(6):
      Mitochondria are highly dynamic, double-membrane organelles that play integral roles beyond energy production. Mitochondria adapt their morphology to meet diverse cellular demands, and highly plastic mitochondrial networks interact and communicate with various cellular components to maintain cellular health. Advances in both light and electron microscopy (EM) have greatly enhanced our understanding of mitochondrial structure and function. However, the small diameter of mitochondrial tubules, often near the diffraction limit of light, poses challenges for visualizing submitochondrial structures and protein distributions with conventional microscopy. Recently, super-resolution microscopy has offered unprecedented insights into mitochondrial dynamics, interactions and architecture. In this Review, we discuss how imaging techniques have advanced our understanding of mitochondrial biology. We critically assess the contributions of two-dimensional EM to elucidating the native architecture of cristae and respiratory chain complexes. Additionally, we explore how three-dimensional EM and super-resolution methods have reshaped our comprehension of mitochondrial network dynamics, heterogeneity and interactions with other cellular components. Finally, we discuss the strengths and limitations of various approaches, considering their potential to overcome current challenges and open new avenues in mitochondrial research, and illuminate how advanced microscopy continues to drive discoveries in mitochondrial biology with implications for metabolic diseases and aging.
    Keywords:  CLEM; Confocal; EM; Mitochondria; Super-resolution microscopy; Volume EM
    DOI:  https://doi.org/10.1242/jcs.263933
  27. Nat Cancer. 2026 Apr 03.
      Multiple single-cell and spatial genomics tools have transformed our ability to deconvolve intricate diseases, including cancer. Analysis of complex, multimodal data has provided insights into genomics, cellular states and interactions in tumor ecosystems, enabling the dissection of salient biology and expanding our understanding of drug response, resistance and target discovery. However, several challenges remain before these methods can achieve their full clinical potential. Here, we discuss opportunities, barriers and potential solutions, including sample acquisition and preservation approaches, profiling methods and analytical tools for heterogeneous populations, and we provide recommendations for robust, reproducible use of these technologies in clinical settings.
    DOI:  https://doi.org/10.1038/s43018-026-01142-1
  28. Adv Sci (Weinh). 2026 Mar 30. e23112
      To initiate distant metastasis via hematogenous dissemination, circulating tumor cells (CTCs) must survive shear-induced destruction in vasculature. However, how CTCs withstand such mechanical interrogation remains poorly understood. Using both patient-derived primary cells and cancer cell lines, this study reports that non-adherent tumor cells mechanically adapt to increasing fluid shear stress (FSS) through re-distribution of activated myosin into cytoplasm. Cytoplasmic but not cortical myosin attenuates force transmission from cell surface into chromatin by disrupting the binding of myosin with actin, which is recapitulated by a cytoskeletal fluidization-based model. Under high FSS, Lamin A/C-mediated nuclear mechanosensing elevates nuclear envelop tension and triggers calcium release from endoplasmic reticulum, which redistributes myosin into cytoplasm through Rho-associated protein kinase. Targeting cytoplasmic myosin-mediated mechanoadaptation restores mechanoresponses and re-sensitizes CTCs to shear-induced death, which eventually reduces tumor metastasis. In summary, these results unveil the reduction of force transmission of CTCs in response to harsh shearing via cytoplasmic myosin accumulation, which potentiates mechanoadaptation and protects them from shear-induced apoptosis during hematogenous metastasis.
    Keywords:  circulating tumor cell; fluid shear stress; force transmission; mechanoadaptation; mechanobiology; mechanotransduction
    DOI:  https://doi.org/10.1002/advs.202523112
  29. Oncogene. 2026 Mar 28.
      Cell competition is an evolutionarily conserved quality control mechanism that eliminates less-fit cells to ensure optimal tissue integrity during development, homeostasis, and regeneration. Beyond these physiological roles, recent evidence implicates a role for cell competition in disease, particularly in cancer, where it can function by either suppressing or promoting malignant progression. In this review, we provide an overview of the different molecular mechanisms that drive cell competition and their impact on cancer development and progression. We will evaluate the current state-of-the-art in vitro experimental systems that can be employed to study these processes. Ranging from classical 2D co-culture systems to advanced organoid and organ-on-chip platforms, these model systems collectively enhance our understanding of the complex cellular interactions that underlie the competitive differences between cells. By integrating insights from diverse model systems, we highlight how cell competition shapes tumor dynamics and discuss how this knowledge could inspire novel therapeutic strategies to prevent or control tumor growth.
    DOI:  https://doi.org/10.1038/s41388-026-03751-7